Howard Burris

10PUBLICATIONS
97CO-AUTHORS
Cancer cell biologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 07, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Alison M Schram, Abdul Rafeh Naqash, Eric B Haura

|Jun 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.

Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney

|Mar 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Reinhard Dummer, Shahneen Sandhu, Wilson H Miller

|Mar 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.

William D Tap, Gregory M Cote, Howard Burris

Pageof 2